公开(公告)号：US20230330164A1

公开(公告)日：2023-10-19

申请号：US17798052

申请日：2021-03-09

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE

IPC: A61K35/747 ,  A61K38/40 ,  A61K35/745 ,  A61P31/14 ,  A61K9/127 ,  A61K31/198 ,  A61K31/728

CPC classification number: A61K35/747 ,  A61K38/40 ,  A61K35/745 ,  A61P31/14 ,  A61K9/127 ,  A61K31/198 ,  A61K31/728 ,  C12R2001/225

Abstract: The present invention relates to a composition comprising lactoferrin and, optionally, probiotic bacterial strains and/or N-acetylcysteine and/or hyaluronic acid for oral use as an antiviral agent, preferably for use in the treatment of viral infections of the a respiratory system from a SARS-coronavirus (e.g. COVID-19).

公开(公告)号：US20220409676A1

公开(公告)日：2022-12-29

申请号：US17774432

申请日：2020-11-05

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE

IPC: A61K35/744 ,  A23L33/185 ,  A23L33/135 ,  A23L33/17 ,  A61K35/745 ,  A61K35/747 ,  A61P1/00 ,  A61P3/00

Abstract: Compositions are described and related methods and food products for increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, based on a mixture M including at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760. Furthermore, the mixture M is described, as well as the compositions and related methods and food products based on mixture M and further comprises at least one protein, preferably proteins of plant origin, or a peptide or an amino acid.

公开(公告)号：US20190290706A1

公开(公告)日：2019-09-26

申请号：US16308330

申请日：2017-06-08

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE ,  Ruggero ROSSI

IPC: A61K35/747 ,  A61K36/064 ,  A61P1/00 ,  A61K9/00 ,  A61K35/745

Abstract: The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of the symptoms of and/or for treating Irritable Bowel Syndrome (IBS) or also similar pathologies affecting the gastrointestinal apparatus. In particular, the bacteria are selected from the following genera: Lactobacillus, Bifidobacterium, Bacillus, Propionibacterium, Streptococcus, Lactococcus, Aerococcus and Enterococcus.

公开(公告)号：US20220354910A1

公开(公告)日：2022-11-10

申请号：US17762017

申请日：2020-09-21

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE

IPC: A61K35/747 ,  A61K35/745 ,  A61P29/00 ,  A61K36/45

Abstract: A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries. and a related method wherein the composition is an immunomodulatory and anti-inflammatory agent are described.

公开(公告)号：US20200061141A1

公开(公告)日：2020-02-27

申请号：US16465511

申请日：2017-12-01

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Ruggero ROSSI ,  Walter FIORE ,  Silvia SALAMINA

IPC: A61K36/45 ,  A61K31/353 ,  A61K9/28

Abstract: The present invention relates to a composition which comprises a mixture which comprises or, alternatively, consists of an extract (a) of a fruit of at least one plant of the genus Vaccinium and at least one ingredient (b) acceptable for pharmaceutical or food use and the use thereof in the prevention and/or treatment of diverticular disease or of a pathology deriving therefrom or correlated thereto.

公开(公告)号：US20160296569A1

公开(公告)日：2016-10-13

申请号：US14916961

申请日：2014-09-05

Applicant: SOFAR S.P.A.

Inventor： Simone Domenico GUGLIELMETTI ,  Ruggero ROSSI ,  Walter FIORE ,  Andrea BIFFI

IPC: A61K35/747 ,  A61K9/48 ,  A61K9/00

CPC classification number: A61K35/747 ,  A23L33/135 ,  A23L33/21 ,  A23V2002/00 ,  A23Y2220/63 ,  A61K9/0053 ,  A61K9/48 ,  A61K2035/11 ,  A61P1/00 ,  A23V2200/32 ,  A23V2200/3202 ,  A23V2200/3204

Abstract: The present invention relates to the use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.

Abstract translation: 本发明涉及包含细菌的组合物增加丁酸，叶酸或烟酸的肠内产生和/或降低琥珀酸的肠内产生的用途。 此外，本发明涉及所述组合物用于治疗和/或预防肠内丁酸酯和/或琥珀酸依赖性病理状况的用途。 特别地，用于治疗和/或预防肠道炎症，腹泻，溃疡性结肠炎或肠道共病。

公开(公告)号：US20220339216A1

公开(公告)日：2022-10-27

申请号：US17761980

申请日：2020-09-21

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE

IPC: A61K35/745 ,  A61K35/747 ,  A61P1/00

Abstract: Compositions comprising a mixture comprising the bacterial strain Bifidobacterium bifidum MIMBb23sg or BbfIBS01 (DSM 32708), at least one or more bacterial strains selected from group A comprising the strains B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BlIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) and, optionally, at least one further bacterial strain selected from a bacterial strain L. casei DG® (CNCM I-1572) and a bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.

公开(公告)号：US20220325234A1

公开(公告)日：2022-10-13

申请号：US17761843

申请日：2020-09-21

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE

IPC: C12N1/20 ,  A61K35/745 ,  A61K35/747 ,  A61P1/00

Abstract: Bacterial strains including B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BIIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) are described. Furthermore, compositions are further described comprising a mixture of at least one or more of the aforementioned bacterial strains and, optionally, at least one further bacterial strain, selected from a bacterial strain L. casei DG® (CNCM I-1572) and bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, irritable bowel syndrome (IBS).

公开(公告)号：US20220313753A1

公开(公告)日：2022-10-06

申请号：US17620648

申请日：2020-07-08

Applicant: SOFAR S.P.A.

Inventor： Simone Domenico GUGLIELMETTI ,  Valentina TAVERNITI ,  Andrea BIFFI ,  Walter FIORE

IPC: A61K35/745 ,  A61P1/00 ,  A61K9/00

Abstract: The present invention relates to a bacterial strain of Bifidobacterium bifidum MIMBb23 sg (=BbfIBSCM) DSM 32708, compositions comprising said bacterial strain and the use thereof in methods for the treatment of gastrointestinal disorders, in particular functional gastrointestinal disorders, such as, for example, irritable bowel syndrome (IBS) or inflammatory bowel diseases (IBDs).

公开(公告)号：US20210236565A1

公开(公告)日：2021-08-05

申请号：US16467797

申请日：2017-12-15

Applicant: SOFAR S.P.A.

Inventor： Andrea BIFFI ,  Walter FIORE ,  Ruggero ROSSI

IPC: A61K35/747 ,  A23L33/135 ,  A61K35/745 ,  A61K36/06 ,  A61K9/00 ,  A61K9/48

Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.